Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

The dose of semaglutide was increased from 0.25 mg in the first 4 weeks to 1.0 mg in week 9. The primary outcome was objective self-administration measured via the maximum breath alcohol ...

1,5 In this prespecified secondary analysis of the SELECT trial, semaglutide 2.4 mg reduced total events (first and subsequent) by 22% (MR 0.78 ... 195 Countries over 25 Years.

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

25). 1 "Real-world analyses such ... 1 Revised MACE-5 occurred in 88 (0.94%) of the 9,321 patients in the semaglutide 2.4 mg group and 288 (1.54%) of 18,642 patients in the non-user group.